advertisement
|
|
|
|
|
advertisement
|
|
Top Stories
Updates on COVID-19 vaccine candidates, FDA policies, company partnerships, and more.
/ read more /
Funding from the US government could lead to 300 million coronavirus vaccine doses by October 2020.
/ read more /
|
|
| |
Industry News
The Trump Administration has awarded a hefty contract to a new pharmaceutical manufacturing consortium to produce in the United States all components of certain critical medicines needed to combat COVID-19.
/ read more /
This latest round of funding adds 14 new technology projects, workforce development, and Global Health Fund projects to NIIMBL's portfolio.
/ read more /
More Industry News
|
|
|
Supplier News
The companies have entered into a partnership worth more than $231 million to provide GSK with added capacity to manufacture and supply its biopharmaceutical therapies.
/ read more /
The 60,000-square-foot facility will work in conjunction with the company’s Kakegawa, Japan, clinical supply facility to serve local and global biotech and pharmaceutical companies.
/ read more /
More Supplier News
|
|
|
|
advertisement
|
Subscribe
Subscribers can enjoy each full issue of Pharm Tech in print, or via Pharm Tech apps.
subscription offers
|
 |
|
| |
|
| |
 |
| |
 |
| |
 |
| |
 |
|
|
Bio/Pharma News
CanSinoBIO will license-in Precision NanoSystems' proprietary RNA vaccine platform technology while the latter leads the development of the RNA vaccine formulation.
/ read more /
The companies have formed a collaboration to develop a novel human recombinant protein as a therapeutic candidate against COVID-19.
/ read more /
More Bio/Pharma News
|
| |
| |
Regulatory News
The International Coalition of Medicines Regulatory Authorities held a virtual meeting of regulators from around the world to discuss policy issues and regulatory requirements to respond to the ongoing COVID-19 pandemic.
/ read more /
The European Medicines Agency is emphasizing the need for the research community to pool resources to determine which COVID-19 treatments and preventions are safe and effective.
/ read more /
More Regulatory News
|
| |
|
Featured Topics |
|
MANUFACTURING
Bioprocessing advances improve product yield, cut costs, and streamline integration between upstream and downstream processes.
/ read more /
|
|
|
QUALITY SYSTEMS
Having a better understanding about compliance will be of benefit when looking for a job or for furthering one’s career, says Siegfried Schmitt, PhD, vice-president, technical, Parexel Consulting.
/ read more /
|
|
|
| |
|
DEVELOPMENT
Reformulation strategies can provide drug developers with a head start to achieve promising options that benefit the patient.
/ read more /
|
|
|
|
|
FORMULATION
Light obscuration testing is the preferred method of sub-visible particle quantification but is not suitable for every preparation.
/ read more /
|
|
|
| |
|
|
| |
ON DEMAND WEBCASTS
Innovation, Collaboration, and Technology Development - Leveraging the Thermo Fisher Ecosystem to Accelerate Platform Improvements in Biopharmaceutical Manufacturing
On Demand
Learn More
|
| |
WEBCASTS
Best Practices for Meeting and Exceeding Regulatory Standards in Primary Packaging USP <381> and <382>
Part II: Wednesday, July 22, 2020 at 10am EDT | 9am CDT | 3pm BST | 4pm CEST
Learn More
Comprehensive Analysis into Disintegration Mechanisms: How Reliable Are Textbook Recommendations?
Wednesday, June 10, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
Learn More
Discovery, Formulation, and Performance of Self-Emulsifying Drug Delivery Systems (SEDDS)
Thursday June 4, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
Learn More
Adopting a Data-Centric Quality Mindset
Thursday, May 28, 2020 at 2pm EDT| 1pm CDT| 11am PDT
Learn More
Your Clinical Results Look Promising, but are you ready for launch? How to build a Robust Packaging Strategy for Rapid Commercialization
Wednesday, June 17, 2020 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST
Moderator: Rita Peters, Editorial Director, Pharmaceutical Technology
Learn More
|
| |
eBOOKS
 |
The Pharmacopoeia Compliance Series features a description of ways bio/pharma companies can participate in monograph development, a practical approach to pharmacopoeial compliance, and a summary of this 12-part series.
|
|
|
|
|
|
